Source comparison
Best Thymosin Alpha-1 Dosage HIV Support 2026: Comparison
Low-Dose (0.8–1.6mg) Twice weekly 12–24 weeks +22–45 cells/µL 8–12% Subtherapeutic in most HIV contexts. Lacks sufficient TLR2 activation to overcome chronic inflammation. Considered obsolete as of 2024. Standard-Dose (3.2mg) +89–107 cells/µL 12–18% The eviden
This comparison does not assign a generated winner or score.
- Low-Dose (0.8–1.6mg)
- Twice weekly
- 12–24 weeks
- +22–45 cells/µL
- 8–12%
- Subtherapeutic in most HIV contexts. Lacks sufficient TLR2 activation to overcome chronic inflammation. Considered obsolete as of 2024.
- Standard-Dose (3.2mg)
- +89–107 cells/µL
- 12–18%
- The evidence-backed standard. Balances efficacy with tolerability. This is the dosing tier with the most Phase III data in HIV populations.
- High-Dose (6mg)
- +91–110 cells/µL
- 28–34%
- No additional CD4+ benefit vs 3.2mg dose. Higher local reactogenicity without improved immunological outcomes. Not cost-justified.
- Pulsed Protocol (3.2mg)
- Twice weekly for 12 weeks, then once weekly maintenance
- 24+ weeks
- +78–94 cells/µL (sustained at 48 weeks)
- 10–15%
- Emerging protocol. Uses intensive loading phase followed by maintenance dosing to sustain thymic output gains. Requires further validation.
- The clinical reality: 3.2mg twice weekly for a minimum of 12 weeks represents the standard of care in research contexts as of 2026. Protocols shorter than 12 weeks rarely produce measurable immune reconstitution because thymic regeneration operates on a timescale of weeks to months, not days.